extra capillary proliferative and segmenting extra capillary proliferative lesions partially the tangles, cariorexis and fibrinoid necrosis. e, f: Masson's trichome stain, interstitium tubular with fibrosis and atrophy, scant infiltrate inflammatory whith lymphocytes and cells plasmatic, tubular epithelium with regenerative changes accentuated and intratubular proteinaceous material. Negative immunofluorescence (IgA, G4, kappa, C3), not showed.

https://doi.org/10.1016/j.aohep.2024.101433

## Demographic and clinical characteristics of patients with chronic HCV infection in a thirdlevel IMSS Hospital in Mexico City

Areli Torres-Castro, Christopher J. Toranzo-González, Javier I. Carrillo-Rojas, Sarahi Ontiveros-López, Iván A. Borunda-Sáenz, Carlos M. Del Real-Calzada, Mauricio Castillo-Barradas, María T. Rizo-Robles

IMSS, UMAE Hospital of Specialties "Dr. Antonio Fraga Mouret", CMN "La Raza"

Introduction and Objectives: : Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, there are approximately 71 million infected individuals worldwide, up to 40% of them will have spontaneous resolution and60% will develop chronic infection with risk of developing cirrhosis and hepatocellular carcinoma. In Mexico it is the fourth cause of death and one of the main causes of disability. Current HCV treatment with direct-acting antivirals (ADDs) has a high rate of sustained viral response that ensures the cure of the infection, decreases the progression of liver fibrosis and decompensation rates in patients with cirrhosis. This study aimed to describe the demographic and clinical characteristics of patients with chronic HCV infection, treated at a third-level care hospital in Mexico City.

**Materials and Patients:** A retrospective cohort study in a part of the patients from the HCV clinic of an IMSS third-levelhospital, which included cases with confirmed HCV infection, who received treatment with direct-acting antivirals +/- ribavirin, in the period of 2017-2022.

**Results:** Data from 222 treated patients was collected; a mean age of 53 years was reported, with a male-female ratio of 1:1. Among candidates for treatment with direct-acting antivirals 50.5% had advanced chronic liver disease at the time of diagnosis. Of these patients 76.1% were classified as a compensated chronic liver disease with a stage of Child Pugh A and 86.7% had a MELD-Na score of less than 14 points. The sustained virologic response rate in this population was 99%.

**Conclusions:** It was observed that the collected treated population was on average in the sixth decade of life, with no gender predilection. Half of this population had advanced chronic liver disease at the time of diagnosis and initiation of treatment with direct antivirals. The majority of patients were in a compensated stage by Child Pugh, and showed a low MELD-Na score which was favorable for follow-up and subsequent management.

#### **Ethical statement**

The protocol was registered and approved by the Ethics Committee. The identity of the patients is protected. Consentment was obtained.

### **Declaration of interests**

None

#### **Funding**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.





Table 1. Prevalence of ages.



**Table 2.** Prevalence of Child-Pugh stage.

https://doi.org/10.1016/j.aohep.2024.101434

# Factors associated with mortality in patients with cirrhosis.

Karina Cazarin-Chávez<sup>1</sup>, María F. Higuera-De La Tijera<sup>1</sup>, Daniel Santana-Vargas<sup>2</sup>, Diego F. Abendaño-Rivera<sup>1</sup>, Cristian Y. Sánchez-Sánchez<sup>1</sup>, José L. Pérez-Hernández<sup>1</sup>

<sup>1</sup> Department of Gastroenterology and Hepatology General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico

<sup>2</sup> Research Department General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico

**Introduction and Objectives:** Chronic liver disease is increasingly prevalent, the causes range from MAFLD, alcohol consumption, HCV, autoimmune disease, and others. They develop complications such as: portal hypertension with esophageal and gastric varices, hepatic encephalopathy, ascites, renal injury, among others, conditioning the final stage of the disease and death; therefore, knowing the factor that has the greatest impact on mortality is relevant. To evaluate which decompensations are associated with higher mortality in patients with cirrhosis of different etiologies.

**Materials and Patients:** Retrospective, analytical, observational study of patients with cirrhosis. To determine the factors associated with 28- and 90-day mortality, proportional hazard curves were performed for COX with encephalopathy, gastrointestinal bleeding, ascites, renal injury, ACLF and infection, with absence of the factor as reference. Considering significant  $\alpha \leq 0.05$ , SPSS-V 25.0 was used

**Results:** 200 patients, men 53%, women 47%. Etiology: alcohol 86, MAFLD 58, autoimmune 27, dual 16 and HCV 13; 37 died at 28 days and 49 at 90 days. Cumulative mortality rate 28 days 18.4%, 90 days 24.4%, with CHI square test for the model was significant, 109.34 (10), p<0.001, being significant with WALD statistic for ACLF with OR of 4.78 (1.24-18.37;95%IC), p=0.023 for 90 days, the model was significant CHI square 118.22 (10), p<0.001, being significant encephalopathy grade 2 OR of 11.95 (1.49-57.16;95%IC) p= 0.02, ascites OR 2.63 (1.24-5.58;95%IC) p=0.12, acute kidney injury OR 4.02 (1. 16-